Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 93

Similar articles for PubMed (Select 24735474)

1.

A comparison of computational models with and without genotyping for prediction of response to second-line HIV therapy.

Revell AD, Boyd MA, Wang D, Emery S, Gazzard B, Reiss P, van Sighem AI, Montaner JS, Lane HC, Larder BA.

HIV Med. 2014 Aug;15(7):442-8. doi: 10.1111/hiv.12156. Epub 2014 Apr 15.

PMID:
24735474
2.

Computational models can predict response to HIV therapy without a genotype and may reduce treatment failure in different resource-limited settings.

Revell AD, Wang D, Wood R, Morrow C, Tempelman H, Hamers RL, Alvarez-Uria G, Streinu-Cercel A, Ene L, Wensing AM, DeWolf F, Nelson M, Montaner JS, Lane HC, Larder BA; RDI study group.

J Antimicrob Chemother. 2013 Jun;68(6):1406-14. doi: 10.1093/jac/dkt041. Epub 2013 Mar 13.

3.

An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes.

Revell AD, Wang D, Wood R, Morrow C, Tempelman H, Hamers R, Alvarez-Uria G, Streinu-Cercel A, Ene L, Wensing A, Reiss P, van Sighem AI, Nelson M, Emery S, Montaner JS, Lane HC, Larder BA; RDI Study Group.

J Antimicrob Chemother. 2014 Apr;69(4):1104-10. doi: 10.1093/jac/dkt447. Epub 2013 Nov 24.

4.

HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.

Puthanakit T, Jourdain G, Hongsiriwon S, Suntarattiwong P, Chokephaibulkit K, Sirisanthana V, Kosalaraksa P, Petdachai W, Hansudewechakul R, Siangphoe U, Suwanlerk T, Ananworanich J; HIV-NAT 086Study Team.

HIV Med. 2010 Oct 1;11(9):565-72. doi: 10.1111/j.1468-1293.2010.00828.x. Epub 2010 Mar 25.

PMID:
20345882
5.

Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy.

Humphreys EH, Chang LW, Harris J.

Cochrane Database Syst Rev. 2010 Jun 16;(6):CD006517. doi: 10.1002/14651858.CD006517.pub3. Review.

PMID:
20556768
6.

Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.

Santoro MM, Sabin C, Forbici F, Bansi L, Dunn D, Fearnhill E, Boumis E, Nicastri E, Antinori A, Palamara G, Callegaro A, Francisci D, Zoncada A, Maggiolo F, Zazzi M, Perno CF, Ceccherini-Silberstein F, Mussini C.

HIV Med. 2013 Oct;14(9):571-7. doi: 10.1111/hiv.12044. Epub 2013 May 13.

7.

Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.

Haupts S, Ledergerber B, Böni J, Schüpbach J, Kronenberg A, Opravil M, Flepp M, Speck RF, Grube C, Rentsch K, Weber R, Günthard HF; Swiss HIV Cohort Study.

Antivir Ther. 2003 Oct;8(5):443-54.

PMID:
14640392
8.

Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).

Vray M, Meynard JL, Dalban C, Morand-Joubert L, Clavel F, Brun-Vézinet F, Peytavin G, Costagliola D, Girard PM; Narval Trial Group.

Antivir Ther. 2003 Oct;8(5):427-34.

PMID:
14640390
9.

The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.

Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N, Fiscus SA, Nelson JA, Eron JJ, Kumwenda J.

AIDS. 2009 Jun 1;23(9):1127-34. doi: 10.1097/QAD.0b013e32832ac34e.

10.

Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.

Pujades-Rodríguez M, O'Brien D, Humblet P, Calmy A.

AIDS. 2008 Jul 11;22(11):1305-12. doi: 10.1097/QAD.0b013e3282fa75b9.

PMID:
18580610
11.

A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy.

Wang D, Larder B, Revell A, Montaner J, Harrigan R, De Wolf F, Lange J, Wegner S, Ruiz L, Pérez-Elías MJ, Emery S, Gatell J, D'Arminio Monforte A, Torti C, Zazzi M, Lane C.

Artif Intell Med. 2009 Sep;47(1):63-74. doi: 10.1016/j.artmed.2009.05.002. Epub 2009 Jun 12.

PMID:
19524413
12.

The development of artificial neural networks to predict virological response to combination HIV therapy.

Larder B, Wang D, Revell A, Montaner J, Harrigan R, De Wolf F, Lange J, Wegner S, Ruiz L, Pérez-Elías MJ, Emery S, Gatell J, Monforte AD, Torti C, Zazzi M, Lane C.

Antivir Ther. 2007;12(1):15-24.

PMID:
17503743
13.
14.

Profile of HIV-infected patients receiving second-line antiretroviral therapy in a resource-limited setting in Nigeria.

Onyedum CC, Iroezindu MO, Chukwuka CJ, Anyaene CE, Obi FI, Young EE.

Trans R Soc Trop Med Hyg. 2013 Oct;107(10):608-14. doi: 10.1093/trstmh/trt071. Epub 2013 Aug 19.

PMID:
23959002
15.

Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study.

Gianotti N, Mondino V, Rossi MC, Chiesa E, Mezzaroma I, Ladisa N, Guaraldi G, Torti C, Tarquini P, Castelli P, Di Carlo A, Boeri E, Keulen W, Kenna PM, Lazzarin A; Mutations and Salvage (MuSa) Study Group.

Clin Infect Dis. 2006 May 15;42(10):1470-80. Epub 2006 Apr 13.

16.
17.

The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool.

Revell AD, Wang D, Boyd MA, Emery S, Pozniak AL, De Wolf F, Harrigan R, Montaner JS, Lane C, Larder BA; RDI Study Group.

AIDS. 2011 Sep 24;25(15):1855-63. doi: 10.1097/QAD.0b013e328349a9c2.

PMID:
21785323
18.

Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone.

Waters L, Bansi L, Asboe D, Pozniak A, Smit E, Orkin C, Fearnhill E, Dunn D, Phillips A; UK CHIC Study; UK HIV Drug Resustance Database.

Antivir Ther. 2013;18(2):213-9.

PMID:
23653911
19.

HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.

Sungkanuparph S, Kiertiburanakul S, Apisarnthanarak A, Malathum K, Sathapatayavongs B.

Int J STD AIDS. 2007 Dec;18(12):832-4.

PMID:
18073016
20.

Impact of HIV-1 viral load on genotypic characteristics among patients failing non-nucleoside reverse trancriptase inhibitor-based first-line regimens in Northern Thailand.

Praparattanapan J, Kotarathitithum W, Chaiwarith R, Nuntachit N, Sirisanthana T, Supparatpinyo K, Tragoolpua Y.

Southeast Asian J Trop Med Public Health. 2011 Jul;42(4):859-66.

PMID:
22299468
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk